Literature DB >> 21628676

The alpha (α)-glucosidase inhibitor, acarbose, attenuates the blood pressure and splanchnic blood flow responses to intraduodenal sucrose in older adults.

Diana Gentilcore1, Lora Vanis, Judith M Wishart, Christopher K Rayner, Michael Horowitz, Karen L Jones.   

Abstract

BACKGROUND: Postprandial hypotension is an important problem in the elderly and may be triggered by the increase in splanchnic blood flow induced by a meal. Acarbose attenuates the fall in blood pressure (BP) induced by oral sucrose and may be useful in the management of postprandial hypotension. It is not known whether the effect of acarbose on postprandial BP reflects slowing of gastric emptying and/or carbohydrate absorption nor whether acarbose affects splanchnic blood flow. We examined the effects of intraduodenal (ID) acarbose on the BP, heart rate, superior mesenteric artery (SMA) flow, and glycemic and insulin responses to ID sucrose in older participants--this approach excluded any "gastric" effect of acarbose.
METHODS: Eight healthy participants (four male and four female, age 66-77 years) received an ID infusion of sucrose (~6 kcal/min), with or without acarbose (100 mg), over 60 minutes. BP, heart rate, SMA flow, blood glucose, and serum insulin were measured.
RESULTS: Acarbose markedly attenuated the falls in systolic (p < .01) and diastolic (p < .05) BP and rises in heart rate (p < .05), SMA flow (p < .05), blood glucose (p < .01), and serum insulin (p < .05). The maximum fall in systolic BP and peak SMA flow was inversely related on the control day (r(2) = -.53, p < .05) but not with acarbose (r(2) = .03, p = .70).
CONCLUSIONS: We conclude that in healthy older participants receiving ID sucrose, (a) acarbose markedly attenuates the hypotensive response by slowing carbohydrate absorption and attenuating the rise in splanchnic blood flow and (b) the fall in BP is related to the concomitant increase in SMA flow.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21628676     DOI: 10.1093/gerona/glr086

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  9 in total

1.  Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes.

Authors:  Laurence G Trahair; Michael Horowitz; Julie E Stevens; Christine Feinle-Bisset; Scott Standfield; Diana Piscitelli; Christopher K Rayner; Adam M Deane; Karen L Jones
Journal:  Diabetologia       Date:  2015-06-06       Impact factor: 10.122

2.  Role of intestinal peptides and the autonomic nervous system in postprandial hypotension in patients with multiple system atrophy.

Authors:  Takeshi Fukushima; Masato Asahina; Yoshikatsu Fujinuma; Yoshitaka Yamanaka; Akira Katagiri; Masahiro Mori; Satoshi Kuwabara
Journal:  J Neurol       Date:  2012-09-15       Impact factor: 4.849

Review 3.  Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1.

Authors:  Mark F McCarty; James J DiNicolantonio
Journal:  Open Heart       Date:  2015-01-29

4.  Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.

Authors:  Jan-Frederik Schlender; Michaela Meyer; Kirstin Thelen; Markus Krauss; Stefan Willmann; Thomas Eissing; Ulrich Jaehde
Journal:  Clin Pharmacokinet       Date:  2016-12       Impact factor: 6.447

Review 5.  Treatment of type 2 diabetes mellitus in the elderly.

Authors:  Funda Datli Yakaryılmaz; Zeynel Abidin Öztürk
Journal:  World J Diabetes       Date:  2017-06-15

6.  A randomized, crossover study of the acute effects of acarbose and gastric distension, alone and combined, on postprandial blood pressure in healthy older adults.

Authors:  Hung Pham; Laurence Trahair; Liza Phillips; Christopher Rayner; Michael Horowitz; Karen Jones
Journal:  BMC Geriatr       Date:  2019-08-30       Impact factor: 3.921

Review 7.  On the potential of acarbose to reduce cardiovascular disease.

Authors:  Eberhard Standl; Michael J Theodorakis; Michael Erbach; Oliver Schnell; Jaakko Tuomilehto
Journal:  Cardiovasc Diabetol       Date:  2014-04-16       Impact factor: 9.951

8.  Acarbose treatment and the risk of cardiovascular disease in type 2 diabetic patients: a nationwide seven-year follow-up study.

Authors:  Jui-Ming Chen; Cheng-Wei Chang; Ying-Chieh Lin; Jorng-Tzong Horng; Wayne H-H Sheu
Journal:  J Diabetes Res       Date:  2014-07-07       Impact factor: 4.011

9.  Acarbose for Postprandial Hypotension With Glucose Metabolism Disorders: A Systematic Review and Meta-Analysis.

Authors:  Biqing Wang; Junnan Zhao; Qiuxiao Zhan; Rongyanqi Wang; Birong Liu; Yan Zhou; Fengqin Xu
Journal:  Front Cardiovasc Med       Date:  2021-05-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.